healthcare

Key Research on Technologies for Parkinson’s Disease Management Published in IEEE Journal of Biomedical and Health Informatics

London, United Kingdom, 2nd November 2015 – The latest technology advances for the clinical management of Parkinson’s disease are explored in cutting-edge research published today by the IEEE’s Journal of Biomedical and Health Informatics (J-BHI). Authored by distinguished researchers in the field, the papers of the Special Issue on “Enabling Technologies for Parkinson’s Disease Management” are available to download now from the IEEE Xplore® Digital Library via http://jbhi.embs.org/

Parkinson’s disease is the most common neurological movement disorder, with a prevalence of up to 2% in the elderly. The new research published in this Special issue represents the edge between the current technical abilities of engineering solutions and clinical applications for the management of Parkinson’s disease, spanning wearable technologies and the Internet of Things, body sensor networks and smart home techniques.

ELC Group in early-stage development of novel influenza vaccine

Cambridge, UK, 16th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has signed up for the early-stage development of a novel vaccine targeting prevention of influenza. The project signals ELC Group’s entry into the pharmaceutical development market.

The vaccine development will be overseen by a specialist R&D team at ELC Group, including regulatory vaccines experts who have worked on and regulated a number of key worldwide paediatric vaccines. The highly experience team includes a number of current advisers to the World Health Organisation.

ELC Group expands into pharmaceutical product development market

Cambridge, UK, 9th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas.

The products, currently under development by an ELC Group specialist team at R&D laboratories will be marketed across the US, EU, LATAM, MENA and China. ELC Group estimates that the complete portfolio will generate an estimated value of 2 Billion USD in annual sales after initial launch. ELC Group intends to sign key strategic global partners for licensing and distribution.

The new product portfolio will address a range of therapeutic areas, including oncology, cardiovascular treatment, diabetes and pain management and ophthalmic solutions. The product set is being developed using the very latest techniques, including advanced technologies such as liposome systems and soft gel.

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

Cambridge, UK, 21st April 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.

The contract award is a major endorsement of ELC Group’s new Concept to Commercialisation solution approach, which delivers a highly integrated portfolio of regulatory affairs consultancy services to customers, from the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product.

The major project, which will see two products taken through ELC Group’s end-to-end Concept to Commercialisation service, is expected to be complete by the end of 2016. The customer, one of the top 25 Chinese pharmaceutical companies, is an active pharmaceutical ingredient company that is moving towards the finished formulation business.

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

Cambridge, UK, 24th February 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding its office presence in Prague in the Czech Republic due to accelerating company growth. From May, ELC Group will be occupying nearly 2000 square metres of offices at Danube House, located in the prime River City Prague business district.

The move is being fuelled by ELC Group’s rapidly expanding customer base, which includes recent major contract wins in China and the US. The increased office space will accommodate ELC Group’s growing team of project management staff and subject matter experts, with staff numbers based in the Czech capital set to almost double within the next three months.

Mobile fleet operator sets its sights on European expansion

Gloucester, UK, 3rd February 2015 – The operator of the world’s largest fleet of mobile operating theatres is targeting expansion in Europe in the wake of the ECB’s plan to inject €1.1 trillion into the Eurozone.

Vanguard Healthcare has appointed Mary Smallbone to the newly-created post of Managing Director Europe and is rolling out its UK-developed healthcare technology into mainland Europe.

Smallbone, a qualified theatre nurse, ran regional sales teams for Smith & Nephew before joining Vanguard in 2003 as Director of Sales and Marketing. She added Operations to her portfolio in 2007 and has already overseen contracts for the company in Italy, Belgium, the Netherlands and Sweden.

Vanguard’s main business is providing mobile operating theatres and mobile wards, usually with experienced theatre staff, to NHS and private hospitals in the UK. More than 200,000 patients have been treated on its fleet of 37 mobiles which include three mobile endoscopy units.

Pages

Subscribe to RSS - healthcare